ARCA biopharma, Inc. financial data

Symbol
ABIO on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
10170 Church Ranch Way, Suite 100, Westminster, Colorado
State of incorporation
Delaware
Fiscal year end
December 31
Former names
NUVELO INC (to 1/27/2009), HYSEQ INC (to 1/28/2003)
Latest financial report
Q1 2024 - Apr 25, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.2 K % +29.4%
Debt-to-equity 3.67 % -24.9%
Return On Equity -16.1 % +14.7%
Return On Assets -15.5 % +13.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.5 M shares +0.67%
Common Stock, Shares, Outstanding 14.5 M shares +0.63%
Entity Public Float 20.9 M USD -28.3%
Common Stock, Value, Issued 14 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 14.5 M shares +0.63%
Weighted Average Number of Shares Outstanding, Diluted 14.5 M shares +0.63%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 788 K USD -73.4%
General and Administrative Expense 7.19 M USD +16.9%
Operating Income (Loss) -7.98 M USD +12.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -6 M USD +25%
Earnings Per Share, Basic -0.42 USD/shares +23.6%
Earnings Per Share, Diluted -0.42 USD/shares +23.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.9 M USD -12.1%
Other Assets, Current 767 K USD -9.98%
Assets, Current 36.7 M USD -12.1%
Property, Plant and Equipment, Net 7 K USD -66.7%
Operating Lease, Right-of-Use Asset 17 K USD -94.7%
Other Assets, Noncurrent 12 K USD -33.3%
Assets 36.7 M USD -12.7%
Accounts Payable, Current 529 K USD +44.5%
Employee-related Liabilities, Current 84 K USD -64.3%
Liabilities, Current 1.58 M USD +24.9%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 1.58 M USD +3.47%
Retained Earnings (Accumulated Deficit) -191 M USD -3.25%
Stockholders' Equity Attributable to Parent 35.1 M USD -13.3%
Liabilities and Equity 36.7 M USD -12.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.53 M USD +4.2%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 14.5 M shares +0.63%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.53 M USD +4.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.9 M USD -12.1%
Deferred Tax Assets, Valuation Allowance 55.5 M USD +2.13%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 55.6 M USD +2.08%
Operating Lease, Liability 48 K USD -86.6%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 49 K USD -88%
Property, Plant and Equipment, Gross 222 K USD -3.06%
Operating Lease, Liability, Current 48 K USD -49.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 96 K USD +3.23%
Lessee, Operating Lease, Liability, to be Paid, Year One 93 K USD -26.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1 K USD -98%
Lessee, Operating Lease, Liability, to be Paid, Year Three 100 K USD +4.17%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 25 K USD -75%
Operating Lease, Payments 23 K USD -30.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 63 K USD -29.2%
Share-based Payment Arrangement, Expense 596 K USD +0.51%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%